CYP3A4 and metabolic syndrome: Further studies are needed to determine whether the metabolism of ATO is associated with CYP3A4 or P-gp when patients receive treatment for fungal infections combined with dyslipidemia pharmacotherapy and whether VOR could affect the efficacy and safety of ATO in clinical practice.